Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. (CSTL) delivers innovative diagnostic solutions that transform cancer care through genomic insights. This news hub provides investors and healthcare professionals with essential updates on the company’s advancements in precision oncology diagnostics.
Access authoritative information about CSTL’s latest developments, including new test validations, clinical study results, and strategic partnerships. Our curated collection features earnings reports, regulatory milestones, and research breakthroughs across key focus areas like melanoma diagnostics and pharmacogenomics.
Stay informed about critical updates including:
- FDA-cleared test announcements
- Peer-reviewed study publications
- Financial performance reports
- Collaborative oncology initiatives
- Expanded clinical utility data
Bookmark this page for streamlined access to Castle Biosciences’ verified news. Check regularly for updates that impact diagnostic practices and investment considerations in the genomic testing sector.
Castle Biosciences (CSTL) has partnered with the Colorado Melanoma Foundation to sponsor the Sun Bus, a mobile initiative providing free skin cancer screenings and public education. Starting in May 2021, the Sun Bus will travel through Texas, Colorado, Arizona, and New Mexico. This initiative, highlighted by Dr. Neil Box, aims to raise awareness post-pandemic about the importance of regular health screenings. Castle’s CEO, Derek Maetzold, emphasized their commitment to improving patient outcomes through early detection and personalized care using their genomic diagnostic tests.
Castle Biosciences (Nasdaq: CSTL) announces national sponsorship of the American Academy of Dermatology's "Skin Cancer, Take a Hike!™" program during Skin Cancer Awareness Month. Since 2014, this event raised $1.5 million to promote skin cancer prevention and early detection. The initiative aims to combat skin cancer, which affects approximately 9,500 individuals daily. Castle emphasizes the importance of awareness, prevention, and early detection in improving health outcomes, aligning with AAD's goals of public education and free screenings.
Castle Biosciences (Nasdaq: CSTL) has announced the acquisition of Myriad myPath Laboratory for $32.5 million, aimed at enhancing its skin cancer genomic testing capabilities. This acquisition will allow Castle to integrate the myPath Melanoma 23-gene expression profile test into its offerings, complementing its existing DecisionDx DiffDx-Melanoma test. The transaction, expected to close in approximately four weeks, is anticipated to provide a comprehensive molecular testing solution for difficult-to-diagnose melanocytic lesions, ultimately improving patient diagnosis and treatment pathways.
Castle Biosciences (Nasdaq: CSTL) will release its Q1 2021 financial results and provide a pipeline update on May 10, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results. The company offers personalized genomic tests for skin cancer, including melanoma and squamous cell carcinoma. Stakeholders can access the live event online or by phone. Castle Biosciences is focused on improving cancer treatment decisions through genomic insights.
Castle Biosciences, a skin cancer diagnostics company, will present two significant studies at the American Academy of Dermatology’s Virtual Meeting from April 23-25, 2021. These studies focus on their genomic tests: DecisionDx-Melanoma and DecisionDx-SCC. The DecisionDx-Melanoma study highlights a Class 2B result as a critical predictor of recurrence in stage I melanoma patients, with a recurrence rate of 20.4%. The DecisionDx-SCC study indicates that incorporating this genomic risk profiling can significantly reduce patient sample sizes needed for clinical trials, optimizing healthcare costs and patient management.
Castle Biosciences (Nasdaq: CSTL) showcased its gene expression profile tests at the Dermatology Nurses' Association 2021 Annual Convention. The presentations included the DecisionDx®-Melanoma, which predicts cutaneous melanoma risk, and DecisionDx®-SCC for high-risk squamous cell carcinoma. Data showed DecisionDx-Melanoma's robust predictive ability for recurrence-free survival, outperforming traditional metrics. The DecisionDx DiffDx®-Melanoma enhances diagnostic precision for challenging lesions. The tests aim to improve treatment decisions and patient outcomes by using tumor biology insights.
Castle Biosciences, Inc. (Nasdaq: CSTL) presented data on its skin cancer gene expression tests at the 10th World Congress of Melanoma and 17th EADO Congress. The company showcased its DecisionDx-Melanoma, DecisionDx-SCC, and DecisionDx DiffDx-Melanoma tests, highlighting their effectiveness in predicting melanoma metastasis and improving risk assessment in cutaneous squamous cell carcinoma. Key findings included significant disease-free survival rates among different risk classes and validation of the tests' prognostic values, which may enhance patient management strategies.
Castle Biosciences (Nasdaq: CSTL) presented data on the integration of its DecisionDx-Melanoma test with clinicopathologic features at the 10th World Congress of Melanoma. The test, which predicts sentinel lymph node (SLN) positivity, utilizes an artificial intelligence-based algorithm called i31-GEP, validated in a cohort of 1,674 patients. Key findings include a high negative predictive value of 98% and reclassification of 63% of patients originally at 5-10% SLN positivity risk. These results aim to refine risk assessment and potential pre-surgical decision-making for melanoma patients.
Castle Biosciences (Nasdaq: CSTL) has announced positive results from an independent study published in the American Journal of Surgery, demonstrating the effectiveness of its DecisionDx®-Melanoma test in predicting patient outcomes for cutaneous melanoma. The study, involving 383 patients, showed that high-risk results correlated with increased rates of sentinel lymph node positivity and higher recurrence rates. The findings emphasize the test's ability to provide significant prognostic information beyond traditional staging methods, thereby aiding treatment decisions.
Castle Biosciences (Nasdaq: CSTL) announced the publication of long-term outcomes data for its DecisionDx-Melanoma test, aimed at predicting risks associated with cutaneous melanoma. Published in JCO® Precision Oncology, the study verifies the test's effectiveness in identifying recurrence risk in early-stage melanoma patients, thus extending previous findings. Notably, the test serves as a significant predictor of recurrence-free, distant metastasis-free, and overall survival, enhancing the predictive power when combined with AJCC staging.
